Daclavir (Daclatasvir) is one of the new direct-acting antiviral drugs that target different steps of the hepatitis C virus (HCV) lifecycle. It is the first-ever approved HCV NS5A replication complex inhibitor, meaning it interferes with a protein the virus uses to reproduce.
Daclavir (Daclatasvir) should be combined with other medications, which may include other direct-acting antivirals that work differently – sofosbuvir.
Who can use Daclavir?
Daclavir can be used by people being treated for hepatitis C for the first time (known as ‘treatment-naive’) and for retreatment of people who were not cured with previous interferon-based therapy (known as ‘treatment-experienced’). Daclavir (Daclatasvir) can be used by people with all stages of compensated liver disease including cirrhosis. However, it works better for people with less advanced liver damage.
The safety and effectiveness of daclatasvir for people with HIV and HCV co-infection has not yet been determined, but this is now being tested. Studies have shown that daclatasvir does not have problematic interactions with most widely used HIV drugs. People with HIV and HCV co-infection who want to take daclatasvir should do so under the care of a doctor who has experience treating both HIV and HCV.